TMOD
LIVE

Serial Number

90370290

Owner

A2 Biotherapeutics, Inc.

Attorney

Joi A. White

First Use Date

May 1, 2023

Filing Date

Dec 9, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TMOD Trademark

Serial Number: 90370290

TMOD is a trademark filed by A2 Biotherapeutics, Inc. on December 9, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

A2 Biotherapeutics, Inc. (10 trademarks)

Agoura Hills, CA 91301

Entity Type: 03

Trademark Details

Filing Date

December 9, 2020

Registration Date

Not Registered

First Use Anywhere

May 1, 2023

First Use in Commerce

May 1, 2023

Published for Opposition

September 27, 2022

Goods & Services

pharmaceutical products for the treatment and prevention of cancer; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of proteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer; biological technology platforms consisting of modified cells, cell receptors, proteins and protein complexes for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer; cell platform consisting of modified cells, cell receptors, proteins and protein complexes for autologous and allogeneic cell manufacturing; therapeutics and cell therapies in the nature of proteins and protein complexes targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy products, namely, genetically engineered tissues for transplant purposes

custom manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing of biological cells, proteins, and antibodies for others for treatment and prevention of cancer

Identification and development of, therapeutic targets, namely, proteins and protein complexes, for others for the treatment and prevention of cancer; development of therapeutics and cell therapies for the treatment and prevention of cancer; development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; biotechnology research, development, testing and analysis for the treatment of cancer; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cells, cellular targets, proteins, and antibodies for others

Filing History

STATEMENT OF USE PROCESSING COMPLETE
Apr 21, 2026 SUPC
USE AMENDMENT FILED
Nov 24, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Nov 24, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 12, 2025 EXRA
SOU EXTENSION 5 GRANTED
Aug 11, 2025 EX5G
SOU EXTENSION 5 FILED
May 14, 2025 EXT5
SOU EXTENSION 5 FILED
May 14, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
May 14, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 22, 2024 EXRA
SOU EXTENSION 4 GRANTED
Oct 22, 2024 EX4G
SOU EXTENSION 4 FILED
Oct 22, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 22, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 15, 2024 EXRA
SOU EXTENSION 3 GRANTED
May 14, 2024 EX3G
SOU EXTENSION 3 FILED
May 14, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
May 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 21, 2023 EXRA
SOU EXTENSION 2 GRANTED
Nov 17, 2023 EX2G
SOU EXTENSION 2 FILED
Nov 17, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 17, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 11, 2023 EXRA
SOU EXTENSION 1 GRANTED
May 9, 2023 EX1G
SOU EXTENSION 1 FILED
May 9, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
May 9, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 22, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 27, 2022 NPUB
PUBLISHED FOR OPPOSITION
Sep 27, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 7, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 18, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 17, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 17, 2022 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 13, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 13, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 13, 2022 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 22, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 22, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 22, 2022 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 6, 2022 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Mar 8, 2022 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 19, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 17, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 17, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 18, 2021 GNRN
NON-FINAL ACTION E-MAILED
Aug 18, 2021 GNRT
NON-FINAL ACTION WRITTEN
Aug 18, 2021 CNRT
ASSIGNED TO EXAMINER
May 28, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 16, 2021 NWOS
NEW APPLICATION ENTERED
Dec 12, 2020 NWAP